OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited has initiated its first Phase 2 clinical trial for OK-101, a novel non-opioid treatment designed to address neuropathic corneal pain, a condition lacking FDA-approved therapies. The trial, involving 48 patients, aims to explore the safety and efficacy of OK-101, potentially offering a breakthrough for patients suffering from the debilitating effects of corneal nerve damage. With this step, OKYO Pharma takes a significant move towards providing a much-needed therapeutic option in ophthalmology.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
